Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.

Bera TK, Onda M, Kreitman RJ, Pastan I.

Leuk Res. 2014 Oct;38(10):1224-9. doi: 10.1016/j.leukres.2014.06.014. Epub 2014 Jul 5.

2.

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, Pastan I.

Blood. 2009 Apr 16;113(16):3792-800. doi: 10.1182/blood-2008-08-173195. Epub 2008 Nov 6.

3.

A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.

Hansen JK, Weldon JE, Xiang L, Beers R, Onda M, Pastan I.

J Immunother. 2010 Apr;33(3):297-304. doi: 10.1097/CJI.0b013e3181cd1164.

PMID:
20445350
4.

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.

Kreitman RJ, Pastan I.

Clin Cancer Res. 2011 Oct 15;17(20):6398-405. doi: 10.1158/1078-0432.CCR-11-0487. Review.

5.

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, Pastan I.

Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5742-7. doi: 10.1073/pnas.1102746108. Epub 2011 Mar 21.

6.

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I.

Clin Cancer Res. 2005 Feb 15;11(4):1545-50.

8.

Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.

Liu X, Müller F, Wayne AS, Pastan I.

Mol Cancer Ther. 2016 May;15(5):1053-62. doi: 10.1158/1535-7163.MCT-15-0828. Epub 2016 Mar 3.

9.

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.

Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I.

Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11311-6. doi: 10.1073/pnas.0804851105. Epub 2008 Aug 4.

11.

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I.

J Clin Oncol. 2012 May 20;30(15):1822-8. doi: 10.1200/JCO.2011.38.1756. Epub 2012 Feb 21.

12.

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.

Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, Stetler-Stevenson M, Fitzgerald DJ, Pastan I.

Clin Cancer Res. 2010 Mar 15;16(6):1894-903. doi: 10.1158/1078-0432.CCR-09-2980. Epub 2010 Mar 9.

13.

CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.

Alderson RF, Kreitman RJ, Chen T, Yeung P, Herbst R, Fox JA, Pastan I.

Clin Cancer Res. 2009 Feb 1;15(3):832-9. doi: 10.1158/1078-0432.CCR-08-1456.

14.

Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.

Wei H, Xiang L, Wayne AS, Chertov O, FitzGerald DJ, Bera TK, Pastan I.

Proc Natl Acad Sci U S A. 2012 May 1;109(18):6898-903. doi: 10.1073/pnas.1204523109. Epub 2012 Apr 16.

15.

Immunotoxins with decreased immunogenicity and improved activity.

Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R.

Leuk Lymphoma. 2011 Jun;52 Suppl 2:87-90. doi: 10.3109/10428194.2011.573039. Epub 2011 Apr 19.

PMID:
21504287
16.

Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys.

Wang B, Liang M, Yao Z, Vainshtein I, Lee R, Schneider A, Zusmanovich M, Jin F, O'Connor K, Donato-Weinstein B, Iciek L, Lavallee T, Roskos L.

J Pharm Sci. 2013 Jan;102(1):250-61. doi: 10.1002/jps.23343. Epub 2012 Oct 22.

PMID:
23090886
17.

Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor.

Saito T, Kreitman RJ, Hanada S, Makino T, Utsunomiya A, Sumizawa T, Arima T, Chang CN, Hudson D, Pastan I, et al.

Cancer Res. 1994 Feb 15;54(4):1059-64.

PMID:
8313362
19.

The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.

Kawa S, Onda M, Ho M, Kreitman RJ, Bera TK, Pastan I.

MAbs. 2011 Sep-Oct;3(5):479-86. doi: 10.4161/mabs.3.5.17228. Epub 2011 Sep 1.

20.

Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.

Du X, Beers R, Fitzgerald DJ, Pastan I.

Cancer Res. 2008 Aug 1;68(15):6300-5. doi: 10.1158/0008-5472.CAN-08-0461.

Supplemental Content

Support Center